Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Immune Response HIV vaccines have potential
The vaccines were found to stabilize CD4+ T-cell counts compared with placebo in HIV patients who have not started antiretroviral therapy. The data are from a year-long safety
The vaccines were found to stabilize CD4+ T-cell counts compared with placebo in HIV patients who have not started antiretroviral therapy. The data are from a year-long safety
Over the last several years, an increasing body of evidence points to dysfunctional copper homeostasis in the pathogenesis of Alzheimer's. Recently, a published study demonstrated that consuming a
The study was led by a team at the National Institute of Allergy and Infectious Diseases. The HIV virus has numerous levels of defense but this protein component
The studies demonstrated that GRN163L induces altered tumor cell adhesion in animal models and that it may have additional benefit in the prevention of metastasis. Previous studies demonstrated
The AIDS Healthcare Foundation (AHF) has moved to petition the FDA due to what it believes are questionable marketing tactics for Viagra, which encourages the recreational use of
MCT-475 is indicated as a prospective treatment for metastatic colorectal cancer which is intended to be co-administered with MCT-465, a Toll-like Receptor (TLR) agonist. “Previously we demonstrated that
The price of the 600mg formulation of Stocrin has been reduced by 14.5% to $0.65 per day, or $237.25 per patient per year from $0.76 per day, for
Its primary objective is to demonstrate the safety of Light Infusion Therapy (Litx) with increasing light doses in the treatment of primary or recurrent glioma, including glioblastoma and
Galapagos' service division BioFocus DPI will provide optimization services for a University of Bristol research program focusing on destroying cancer cells. The contract value for Galapagos will exceed
<p>Actavis bought the API division for an undisclosed price. The acquisition provides Actavis with the ability to develop and manufacture its own APIs, the single largest cost component